Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection.

Journal of clinical gastroenterology - 1 Jul 2014

Zhou Kali, Ferguson Jessica, Bau Sherona, Saab Sammy

Abstract excerpt

BACKGROUND: Despite improved virologic response with the addition of direct acting agents to peginterferon and ribavirin treatment in chronic hepatitis C virus (HCV) genotype 1 infection, a subset of patients experience viral breakthrough while on therapy. Defining viral breakthrough and patient characteristics is important for ongoing and future HCV treatment. METHODS: Thirty-four patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 24045279
DOI: 10.1097/MCG.0b013e3182a8824c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection.PMID 24045279Read ↗

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.Semantic proximity Read ↗

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.Semantic proximity Read ↗

Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Semantic proximity Read ↗

Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.Semantic proximity Read ↗

Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.Semantic proximity Read ↗

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.Semantic proximity Read ↗

Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.Semantic proximity Read ↗

Multisite NS5A Resistance Mutations Leading to Virological Breakthrough in Hepatitis C Virus Genotype 1b: A Case ReportSemantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

Management of direct antiviral agent failures.Semantic proximity Read ↗

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.